Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460238 · ClinicalTrials.gov registry record
Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- 29
- Enrollment target
NCT01460238 is a clinical trial that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 29 participants.
The verdict
NCT01460238 has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- 29 participants
- Enrollment target
Study Summary
The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2011-10 |
| Est. Completion | 2018-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01460238
The ClinicalTrials.gov registry entry for NCT01460238 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01460238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01460238 about?
NCT01460238 is a clinical study titled "Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia". The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL pat...
What is the current status of trial NCT01460238?
This trial is currently completed. The enrollment target is 29 participants. The study started on 2011-10. Estimated completion is 2018-05.
Who is sponsoring clinical trial NCT01460238?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.